Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

940.00USD
--
Change (% chg)

-- (--)
Prev Close
$940.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22
52-wk High
$1,231.90
52-wk Low
$788.70

Latest Key Developments (Source: Significant Developments)

Heat Biologics Meets Efficacy Endpoint in Phase 1B Lung Cancer Trial
Monday, 13 Mar 2017 07:00am EDT 

Heat Biologics Inc : Heat biologics meets efficacy endpoint in its phase 1b lung cancer trial to progress to phase 2 . Data monitoring committee (dmc) determined that phase 1b safety endpoint was met . There do not appear to be additional toxicities seen in Hs-110/Nivolumab combination compared to existing data on nivolumab alone .5 out of 15 patients treated with Hs-110/Nivolumab combination had 20% or greater tumor reduction.  Full Article

Bristol-Myers Squibb appoints Thomas Lynch as Chief Scientific Officer
Wednesday, 8 Mar 2017 12:24pm EST 

Bristol-Myers Squibb Co : Bristol-Myers Squibb appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer . Lynch succeeds Francis Cuss who will retire from company . Lynch will step down from Board of Directors of Bristol-Myers Squibb, effective March 15, 2017 .Cuss will serve as an advisor to company for next three months.  Full Article

Bristol-Myers Squibb declared a qtrly div of $0.39 per share
Thursday, 2 Mar 2017 04:34pm EST 

Bristol-Myers Squibb Co :Bristol-Myers Squibb - declared a quarterly dividend of $0.39 per share on $.10 par value common stock of corporation.  Full Article

Bristol-Myers announces equity investment in GRAIL Inc
Wednesday, 1 Mar 2017 08:10am EST 

Bristol-Myers Squibb Co : Bristol-Myers Squibb expands focus on precision medicine with investment and planned collaboration with GRAIL on blood-based cancer screening . Bristol-Myers Squibb Co - Bristol-Myers Squibb will gain early access to Grail's comprehensive clinical trial databases . Bristol-Myers Squibb Co - co, grail agreed to principal terms of a research collaboration for co to examine clinical data using GRAIL's analytic tools .Bristol-Myers Squibb Co - announced its equity investment and plans for a research collaboration with GRAIL Inc.  Full Article

Bristol-Myers Squibb prices $1.5 billion of senior notes
Wednesday, 22 Feb 2017 06:00pm EST 

Bristol-myers Squibb Co :Bristol-Myers Squibb prices $1.5 billion of senior notes.  Full Article

Bristol-Myers sees restructuring charges between $1.5-$2.0 bln through 2020
Tuesday, 21 Feb 2017 12:23pm EST 

Bristol-myers Squibb Co : Bristol-Myers Squibb says expects to incur charges through 2020, ranging between $1.5 billion to $2.0 billion in connection with restructuring announced in Oct 2016 . Bristol-Myers Squibb - Cash outlays in connection with the actions expected to be about 40% to 50% of the total charges .Bristol-Myers Squibb - Charges of about $90 million recognized during Q4, primarily from certain research and development employee workforce reductions and accelerated depreciation on expected early site exits.  Full Article

Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab)
Thursday, 2 Feb 2017 04:15pm EST 

Bristol-myers Squibb Co : Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab) in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer .Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab) in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.  Full Article

FDA grants accelerated approval to Bristol-Myers Squibb's nivolumab
Thursday, 2 Feb 2017 02:33pm EST 

U.S. Food and Drug Administration:Granted accelerated approval to Bristol-Myers Squibb Company's nivolumab for treatment of locally advanced or metastatic urothelial carcinoma.  Full Article

Bristol-Myers squibb announces European Patent Office decision on Sprycel
Wednesday, 1 Feb 2017 12:19pm EST 

Bristol-Myers Squibb Co : Bristol-Myers Squibb announces European Patent Office decision on Sprycel . Bristol-Myers Squibb Co says decision does not impact patents outside of EU or other Sprycel -related patents .Bristol-Myers squibb co says EPO upheld a decision that found patent to be invalid.  Full Article

Bristol-Myers Squibb reports Q4 non-GAAP earnings per share of $0.63
Thursday, 26 Jan 2017 06:59am EST 

Bristol-myers Squibb Co : Bristol-Myers Squibb reports fourth quarter and full year 2016 financial results . Q4 non-GAAP earnings per share $0.63 . Q4 earnings per share $0.53 . Q4 earnings per share view $0.67 -- Thomson Reuters I/B/E/S . Q4 revenue $5.2 billion versus I/B/E/S view $5.12 billion . Bristol-Myers Squibb says adjusts FY 2017 non-GAAP earnings per share outlook to $2.70 to $2.90 . Reaffirms FY 2017 GAAP earnings per share view $2.47 to $2.67 . Confirms 2017 GAAP eps guidance range of $2.47 to $2.67 and adjusts non-GAAP eps guidance range to $2.70 to $2.90 . Sees 2017 worldwide revenues increasing in low-single digits . Qtrly yervoy worldwide revenue $264 million versus $265 million . Sees 2017 gross margin as a percentage of revenue to be approximately 72% to 73% for both GAAP and non-GAAP . qtrly eliquis worldwide revenue $948 million versus $602 million . Q4 opdivo worldwide revenues $1,310 million versus $475 million last year . Q4 sprycel worldwide revenues $494 million versus $429 million last year . FY2017 earnings per share view $2.96 -- Thomson Reuters I/B/E/S .Sees 2017 research and development expenses increasing in high-single digit range for both GAAP and non-GAAP.  Full Article

More From Around the Web

U.S. Supreme Court may limit where companies can be sued

WASHINGTON, April 25 U.S. Supreme Court justices on Tuesday signaled a willingness to place limits on where corporations can be sued in a dispute involving drug maker Bristol-Myers Squibb Co, a potential setback to plaintiffs' lawyers who try to bring suits in friendly courts.